explore -WSS

explore

author：comprehensive 2025-10-02 18:48:20 - browse：494

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Healthy food access boosts outcomes in two studies

leisure time

WSS

See how much Covid

What health policies could hitch a ride on a spending bill?

Type 2 diabetes prevention programs work at large scale: study

A letter from the executive editor: STAT UnitedHealth investigation

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Change Healthcare can notify patients about the breach, HHS says

explore

explore

Wikipedia

Medical records are filled with copy

Let's speed up science by embracing open access publishing

At least 13 dead in Texas as scorching temps continue

Cancer diagnosis changes perspective doctor, former hospital CEO

Moonlake's readout produced a cash windfall. Risks remain

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Intellia reports positive results for its CRISPR

Medical records are filled with copy

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

explore

Ohio still needs to do more to protect the right to abortion

First transplant of an entire human eye performed

Type 2 diabetes prevention programs work at large scale: study

Type 2 diabetes prevention programs work at large scale: study

How to increase colonoscopy rates? Looks like an AI can help

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

entertainment

leisure time

focus

hotspot